Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Update in inclusion body myositis.
[inclusion body myositis]
The
purpose
of
this
study
is
to
review
recent
scientific
advances
relating
to
the
natural
history
,
cause
,
treatment
and
serum
and
imaging
biomarkers
of
inclusion
body
myositis
(
IBM
)
.
Several
theories
regarding
the
aetiopathogenesis
of
IBM
are
being
explored
and
new
therapeutic
approaches
are
being
investigated
.
New
diagnostic
criteria
have
been
proposed
,
reflecting
the
knowledge
that
the
diagnostic
pathological
findings
may
be
absent
in
patients
with
clinically
typical
IBM
.
The
role
of
MRI
in
IBM
is
expanding
and
knowledge
about
pathological
biomarkers
is
increasing
.
The
recent
description
of
autoantibodies
to
cytosolic
5
'
nucleotidase
1
A
in
patients
with
IBM
is
a
potentially
important
advance
that
may
aid
early
diagnosis
and
provides
new
evidence
regarding
the
role
of
autoimmunity
in
IBM
.
IBM
remains
an
enigmatic
and
often
misdiagnosed
disease
.
The
pathogenesis
of
the
disease
is
still
not
fully
understood
.
To
date
,
pharmacological
treatment
trials
have
failed
to
show
clear
efficacy
.
Future
research
should
continue
to
focus
on
improving
understanding
of
the
pathophysiological
mechanisms
of
the
disease
and
on
the
identification
of
reliable
and
sensitive
outcome
measures
for
clinical
trials
.
IBM
is
a
rare
disease
and
international
multicentre
collaboration
for
trials
is
important
to
translate
research
advances
into
improved
patient
outcomes
.
Diseases
Validation
Diseases presenting
"diagnostic pathological findings"
symptom
inclusion body myositis
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom